Genentech Files Avastin sBLA For Relapsed Metastatic Colorectal Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
The application would expand on an October labeling change which added third-line data.
You may also be interested in...
Genentech Halts Enrollment In Avastin Early-Stage Colon Cancer Trial
The firm reports a higher rate of non-colon cancer related deaths in the AVANT trial for adjuvant use of bevacizumab.
Genentech Halts Enrollment In Avastin Early-Stage Colon Cancer Trial
The firm reports a higher rate of non-colon cancer related deaths in the AVANT trial for adjuvant use of bevacizumab.
Genentech Avastin Label Adds Third-Line Data Showing Minimal Efficacy
NCI study of bevacizumab demonstrated a 1% response rate in refractory metastatic colorectal cancer when combined with 5-FU/LV.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: